SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Sonki who wrote (680)4/9/1998 5:55:00 PM
From: muddphudd  Respond to of 1580
 
After some discussion with a colleague at Merck and my broker, I get the impression that we will see a split (3:1) before we see MRK consistently break through the 130 mark.



To: Sonki who wrote (680)4/9/1998 7:23:00 PM
From: Stacy J. Matter  Respond to of 1580
 
Sonki:

MRK gets 0% of it's revenue from Aggrastat(Tirofiban) right now. It hasn't been approved by the FDA yet.

Advisory board decision should be out on Friday(or Monday)

This is not final approval, although the advisory boards decision is a pretty good indication whether or not a drug will be approved


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News